Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14,466 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Nomogram for predicting axillary upstaging in clinical node-negative breast cancer patients receiving neoadjuvant chemotherapy.
Maimaitiaili A, Chen H, Xie P, Liu Z, Ling R, Zhao Y, Yang H, Liu Y, Liu K, Zhang J, Mao D, Yu Z, Liu Y, Fu P, Wang J, Jiang H, Zhao Z, Tian X, Cao Z, Wu K, Song A, Jin F, He J, Fan Z, Zhang H. Maimaitiaili A, et al. Among authors: wu k. J Cancer Res Clin Oncol. 2023 Sep;149(11):8769-8778. doi: 10.1007/s00432-023-04817-9. Epub 2023 May 2. J Cancer Res Clin Oncol. 2023. PMID: 37129606
Concurrent neoadjuvant chemotherapy and estrogen deprivation in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (CBCSG-036): A randomized, controlled, multicenter trial.
Yu KD, Wu SY, Liu GY, Wu J, Di GH, Hu Z, Hou YF, Chen CM, Fan L, Tang LC, Shen ZZ, Wu KJ, Zhuang ZG, Zhang HW, Shao ZM. Yu KD, et al. Cancer. 2019 Jul 1;125(13):2185-2193. doi: 10.1002/cncr.32057. Epub 2019 Mar 20. Cancer. 2019. PMID: 30892700 Free article. Clinical Trial.
Efficacy analysis of neoadjuvant chemotherapy with or without anthracyclines in female patients with HER2-positive breast cancer in China: a nationwide, multicenter, 10-year retrospective study (CSBrS-012).
Chen H, Maimaitiaili A, Liu Z, Ling R, Zhao Y, Yang H, Liu Y, Liu K, Zhang J, Mao D, Yu Z, Liu Y, Fu P, Wang J, Jiang H, Zhao Z, Tian X, Cao Z, Wu K, Song A, Jin F, He J, Fan Z, Zhang H. Chen H, et al. Among authors: wu k. Ther Adv Med Oncol. 2023 Feb 28;15:17588359231156146. doi: 10.1177/17588359231156146. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 36891484 Free PMC article.
Association of a complete breast cancer pathologic response with axillary lymph node metastasis via neoadjuvant chemotherapy: Results from the CSBrS-012 study.
Ma L, Gao P, Liu Z, Jiao D, Ling R, Xiao J, Zhao Y, Wang Y, Yang H, Liu Y, Liu K, Zhang J, Li G, Mao D, Deng Y, He J, Amina M, Yu Z, Fei W, Liu Y, Fu P, Yao M, Wang J, Zhu L, Jiang H, Zhao Z, Tian X, Cao Z, Ma X, Wu K, Fu S, Song A, Wang Y, Feng J, Fan Z. Ma L, et al. Among authors: wu k. Chin Med J (Engl). 2024 Jun 5;137(11):1369-1371. doi: 10.1097/CM9.0000000000002849. Epub 2023 Oct 25. Chin Med J (Engl). 2024. PMID: 37882089 Free PMC article. No abstract available.
Axillary lymph node dissection in triple-negative or HER2-positive breast cancer patients with clinical N2 achieving pathological complete response after neoadjuvant therapy: Is it necessary?
Guo X, Zhang J, Gong X, Wang J, Dai H, Jiao D, Ling R, Zhao Y, Yang H, Liu Y, Liu K, Zhang J, Mao D, He J, Yu Z, Liu Y, Fu P, Wang J, Jiang H, Zhao Z, Tian X, Cao Z, Wu K, Song A, Jin F, Fan Z, Liu Z. Guo X, et al. Among authors: wu k. Breast. 2024 Feb;73:103671. doi: 10.1016/j.breast.2024.103671. Epub 2024 Jan 5. Breast. 2024. PMID: 38277714 Free PMC article.
A nomogram for predicting pathologic node negativity after neoadjuvant chemotherapy in breast cancer patients: a nationwide, multicenter retrospective cohort study (CSBrS-012).
Maimaitiaili A, Li Y, Chai N, Liu Z, Ling R, Zhao Y, Yang H, Liu Y, Liu K, Zhang J, Mao D, Yu Z, Liu Y, Fu P, Wang J, Jiang H, Zhao Z, Tian X, Cao Z, Wu K, Song A, Jin F, Wu P, He J, Fan Z, Zhang H. Maimaitiaili A, et al. Among authors: wu p, wu k. Front Oncol. 2024 May 10;14:1326385. doi: 10.3389/fonc.2024.1326385. eCollection 2024. Front Oncol. 2024. PMID: 38800388 Free PMC article.
Intensive chemotherapy versus standard chemotherapy among patients with high risk, operable, triple negative breast cancer based on integrated mRNA-lncRNA signature (BCTOP-T-A01): randomised, multicentre, phase 3 trial.
He M, Jiang YZ, Gong Y, Fan L, Liu XY, Liu Y, Tang LC, Mo M, Hou YF, Di GH, Liu GY, Yu KD, Wu J, Yan X, Zeng XH, Fu DY, Song CG, Zhuang ZG, Wu KJ, Wang J, Wang ZH, Shao ZM. He M, et al. BMJ. 2024 Oct 23;387:e079603. doi: 10.1136/bmj-2024-079603. BMJ. 2024. PMID: 39442958 Free PMC article. Clinical Trial.
14,466 results
You have reached the last available page of results. Please see the User Guide for more information.